The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...
First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback